Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study) (SEGA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02166853|
Recruitment Status : Completed
First Posted : June 18, 2014
Last Update Posted : March 4, 2016
Numerous trials support the efficacy and safety of volatile anesthetic agents, namely inhalation of sevoflurane through dedicated devices, for the sedation of ICU patients. Several preclinical studies have shown that sevoflurane inhalation improves gas exchange and decreases pulmonary and systemic inflammation in experimental models of acute respiratory distress syndrome (ARDS).
The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of an early 48-hour sevoflurane inhalation on gas exchange and inflammation in patients with ARDS.
|Condition or disease||Intervention/treatment||Phase|
|Acute Respiratory Distress Syndrome||Drug: sevoflurane Drug: midazolam||Phase 4|
Acute respiratory distress syndrome (ARDS) is characterized by hypoxemic respiratory failure that can be lethal in 30 to 60% of patients. Its pathophysiological landmark, diffuse alveolar damage, is associated with alveolar inflammation, epithelial injury and alveolar fluid clairance impairment.
Several preclinical studies have shown that early sevoflurane inhalation improves gas exchange, reduces alveolar edema and attenuates pulmonary and systemic inflammation in experimental models of ARDS.
To date, no clinical trial has assessed the effects of early sevoflurane inhalation in ARDS patients.
The purpose of this prospective, randomized, controlled study is to evaluate the effects of a 48-hour sevoflurane inhalation strategy on gas exchange and both systemic and pulmonary inflammation in the early phase of ARDS.
After inclusion, ICU patients with moderate to severe ARDS (according to the Berlin definition of ARDS criteria; JAMA 2010) will be randomized into two groups :
- a "conventional group", in which intravenous sedation with midazolam will be administered
- a "sevoflurane group", in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices Arterial blood gases will be analyze before randomization and at 24, 48, 72, 96, and 120 hours.
Bronchoalveolar lavages (BAL) and blood samples will be assessed before randomization and at 48 hours, in order to measure tumor necrosis factor-alpha (TNFα), interleukin (IL)-1β, IL-6, IL-8 and sRAGE levels. Duplicate assays will be performed with Multiplex (TNFα/interleukins) or ELISA (sRAGE).
During the 48-hour treatment period, bispectral index (BIS®) values ranging from 40 to 50 will be targeted and neuromuscular blocking agents (cisatracurium) will be administered in both groups. Protective ventilation strategies will be applied, as well as other guidelines or recommendations on the management of ICU patients with ARDS.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study.|
|Study Start Date :||April 2014|
|Actual Primary Completion Date :||February 2016|
|Actual Study Completion Date :||March 2016|
Experimental: conventional group
a "conventional group", in which intravenous sedation with midazolam will be administered
Sedation with intravenous midazolam
Experimental: sevoflurane group
a "sevoflurane group", in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices
Sedation with inhaled sevoflurane
- PaO2/FiO2 ratio [ Time Frame: at 48 hours ]
- - Plasma and alveolar levels of proinflammatory cytokines : tumor necrosis factor alpha (TNFα, interleukin (IL)-1β, IL-6, IL-8 [ Time Frame: at 48 hours ]
- Plasma and alveolar levels of sRAGE [ Time Frame: at 48 hours ]
- PaO2/FiO2 ratio [ Time Frame: at day 1, day 3, day 5 ]
- Lowest PaO2/FiO2 during the first 5 days of the study [ Time Frame: at 5 days ]
- Mean PaO2/FiO2 ratio during the first 5 days of the study [ Time Frame: at 5 days ]
- Pulmonary static compliance, resistance and elastance [ Time Frame: at day 1, day 2 ]
- Duration of controlled mechanical ventilation [ Time Frame: at day 30 ]
- Total duration of mechanical ventilation (controlled/assisted) [ Time Frame: at day 30 ]
- Number of ventilatory-free days [ Time Frame: at day 30 ]
- Number of organ failure-free days [ Time Frame: at day 30 ]
- Vasopressor requirements [ Time Frame: at 48 hours ]
- Mortality [ Time Frame: at day 30 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02166853
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Matthieu JABAUDON||University Hospital, Clermont-Ferrand|